Humankind Investments LLC Sells 1,887 Shares of Boston Scientific Corporation $BSX

Humankind Investments LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 14.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 10,789 shares of the medical equipment provider’s stock after selling 1,887 shares during the period. Humankind Investments LLC’s holdings in Boston Scientific were worth $1,088,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. HM Payson & Co. grew its holdings in shares of Boston Scientific by 1.4% in the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after buying an additional 98 shares during the period. Baldwin Investment Management LLC grew its holdings in shares of Boston Scientific by 1.2% in the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider’s stock valued at $781,000 after buying an additional 102 shares during the period. Park Square Financial Group LLC grew its holdings in shares of Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after buying an additional 103 shares during the period. HHM Wealth Advisors LLC grew its holdings in shares of Boston Scientific by 13.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 103 shares during the period. Finally, Forum Financial Management LP grew its holdings in shares of Boston Scientific by 0.8% in the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider’s stock valued at $1,357,000 after buying an additional 112 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.6%

Shares of NYSE:BSX opened at $103.6440 on Wednesday. The company’s 50-day moving average price is $103.71 and its two-hundred day moving average price is $102.10. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a one year low of $78.08 and a one year high of $108.94. The stock has a market capitalization of $153.57 billion, a PE ratio of 61.69, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the firm posted $0.62 EPS. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research analyst reports. Barclays upped their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $115.00 target price on shares of Boston Scientific in a research note on Wednesday, May 28th. Raymond James Financial upped their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Finally, Oppenheimer upped their target price on shares of Boston Scientific from $110.00 to $118.00 and gave the stock a “market perform” rating in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $117.50.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the company’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock worth $35,976,603 in the last 90 days. 0.50% of the stock is owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.